Half-Life of Quetiapine Extended-Release (Seroquel XR)
The elimination half-life of quetiapine extended-release is approximately 7 hours for the parent compound and approximately 18 hours for its active metabolite N-desalkyl quetiapine (norquetiapine). 1
Pharmacokinetic Profile
The extended-release formulation demonstrates consistent half-life values across different dosing ranges (300-800 mg daily):
- Quetiapine parent compound: ~7 hours
- N-desalkyl quetiapine (active metabolite): ~18 hours 1
These values remain stable regardless of dose, indicating predictable pharmacokinetics across the therapeutic range.
Important Clinical Context for Your Patient
Drug Interaction with Lamotrigine
Your patient's lamotrigine 200 mg daily dose is clinically significant and will reduce quetiapine levels, but this interaction is formulation-dependent:
- For quetiapine XR (which your patient is taking): Lamotrigine does NOT significantly affect quetiapine plasma concentrations, regardless of lamotrigine dose 2, 3
- For quetiapine IR (immediate-release): Lamotrigine doses >200 mg/day reduce quetiapine concentrations by approximately 46%, with 50% of patients falling below therapeutic range 2
The good news: Since your patient is on the XR formulation, the dose reduction from 100 mg to 50 mg is unlikely to be complicated by a lamotrigine interaction. The XR formulation appears protected from this interaction mechanism 2, 3.
Lithium Interaction
Lithium 800 mg daily does not significantly alter quetiapine pharmacokinetics. The FDA label confirms no clinically relevant pharmacokinetic interactions between quetiapine and lithium 4. This combination is well-studied in bipolar disorder trials 4.
Clinical Implications
- Steady-state achievement: Quetiapine XR reaches steady state after approximately 3 days of sequential dosing 1
- Once-daily dosing: The extended-release formulation allows convenient once-daily administration due to the prolonged release profile
- Dose adjustments: The half-life supports the current dose reduction strategy, with full washout of the higher dose occurring within 1-2 days
Key Caveat
While the half-life itself is not affected by lamotrigine in the XR formulation, therapeutic drug monitoring should still be considered if clinical response is suboptimal, as individual variability exists 2.